Acumen Pharmaceuticals Total Liabilities Growth & History (ABOS)
Acumen Pharmaceuticals's total liabilities was $52.4M for fiscal 2025.
View full Acumen Pharmaceuticals company overviewAcumen Pharmaceuticals annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $52.4M | −$4.8M | −8.35% |
| 2024 | 2024-12-31 | $57.2M | $14.0M | +32.50% |
| 2023 | 2023-12-31 | $43.2M | $35.3M | +452.38% |
| 2022 | 2022-12-31 | $7.8M | $2.7M | +51.78% |
| 2021 | 2021-12-31 | $5.1M | −$1.2M | −19.16% |
| 2020 | 2020-12-31 | $6.4M | — | — |
Acumen Pharmaceuticals quarterly total liabilities
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $58.7M | $3.9M | +7.16% |
| Q1 2026 | 2026-03-31 | $46.2M | −$2.8M | −5.73% |
| Q4 2025 | 2025-12-31 | $52.4M | −$4.8M | −8.35% |
| Q3 2025 | 2025-09-30 | $49.0M | −$725,000 | −1.46% |
| Q2 2025 | 2025-06-30 | $54.8M | $9.9M | +21.91% |
| Q1 2025 | 2025-03-31 | $49.0M | $10.0M | +25.75% |
| Q4 2024 | 2024-12-31 | $57.2M | $14.0M | +32.50% |
| Q3 2024 | 2024-09-30 | $49.8M | $43.7M | +716.22% |
| Q2 2024 | 2024-06-30 | $45.0M | $36.4M | +427.09% |
| Q1 2024 | 2024-03-31 | $38.9M | $30.2M | +343.48% |
| Q4 2023 | 2023-12-31 | $43.2M | $35.3M | +452.38% |
| Q3 2023 | 2023-09-30 | $6.1M | −$515,000 | −7.79% |
| Q2 2023 | 2023-06-30 | $8.5M | $3.4M | +65.36% |
| Q1 2023 | 2023-03-31 | $8.8M | $4.8M | +119.58% |
| Q4 2022 | 2022-12-31 | $7.8M | $2.7M | +51.78% |
| Q3 2022 | 2022-09-30 | $6.6M | $5.1M | +344.12% |
| Q2 2022 | 2022-06-30 | $5.2M | $641,000 | +14.19% |
| Q1 2022 | 2022-03-31 | $4.0M | — | — |
| Q4 2021 | 2021-12-31 | $5.1M | −$1.2M | −19.16% |
| Q3 2021 | 2021-09-30 | $1.5M | — | — |
| Q2 2021 | 2021-06-30 | $4.5M | — | — |
| Q4 2020 | 2020-12-31 | $6.4M | — | — |
Acumen Pharmaceuticals total liabilities trends
Over the last five fiscal years, Acumen Pharmaceuticals's total liabilities increased from $6.4M to $52.4M, a change of $46.0M. The latest reported quarter, Q2 2026, shows $58.7M.
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Acumen Pharmaceuticals source filings ↗Community posts
Acumen’s cash falls as November Alzheimer’s trial results approach
Acumen ($ABOS) reported $78.6 million of cash, equivalents and marketable securities at the end of its third quarter of 2026, down from $110.2 million three months earlier. Management expects those resources to fund current clinical and ope ...